Skip to main content
NCBI home page
Elsevier Sponsored Documents logoLink to Elsevier Sponsored Documents
. 2019 Jun 10;35(6):950–952. doi: 10.1016/j.ccell.2019.05.012

Selective Loss of PARG Restores PARylation and Counteracts PARP Inhibitor-Mediated Synthetic Lethality

Ewa Gogola, Alexandra A Duarte, Julian R de Ruiter, Wouter W Wiegant, Jonas A Schmid, Roebi de Bruijn, Dominic I James, Sergi Guerrero Llobet, Daniel J Vis, Stefano Annunziato, Bram van den Broek, Marco Barazas, Ariena Kersbergen, Marieke van de Ven, Madalena Tarsounas, Donald J Ogilvie, Marcel van Vugt, Lodewyk FA Wessels, Jirina Bartkova, Irina Gromova, Miguel Andújar-Sánchez, Jiri Bartek, Massimo Lopes, Haico van Attikum, Piet Borst, Jos Jonkers ∗, Sven Rottenberg ∗∗
PMCID: PMC6561720  PMID: 31185216

Main Text

(Cancer Cell 33, 1078–1093.e1–e12; June 11, 2018)

In the originally published version of this article, the red section (>20%) of the pie chart “Triple-negative breast cancers” in Figure 6D was incorrectly labeled; however, the related numbers stated in the Results section are correct. The correct Figure 6 is now shown here and in the online version of the paper. The authors apologize for any confusion this error may have caused.

graphic file with name gr6c.jpg

Open in a new tab

Figure 6. PARG Depletion in Human Cancer Cells Leads to PARPi Resistance but Results in Acquired Vulnerabilities (corrected)

graphic file with name gr6o.jpg

Open in a new tab

Figure 6. PARG Depletion in Human Cancer Cells Leads to PARPi Resistance but Results in Acquired Vulnerabilities (original)

Contributor Information

Jos Jonkers, Email: j.jonkers@nki.nl.

Sven Rottenberg, Email: sven.rottenberg@vetsuisse.unibe.ch.

RESOURCES